USA

美国

News Group

新闻组

News Commentary

新闻评论

Issued on behalf of Oncolytics Biotech Inc.

代表Oncolytics生物技术公司发布。

VANCOUVER, BC

加拿大温哥华

,

，

Aug. 14, 2025

2025年8月14日

/PRNewswire/ --

/美通社/ --

USA

美国

News Group

新闻组

News Commentary

新闻评论

– Federal budget cuts have

– 联邦预算削减已经

put pressure on cancer research

对癌症研究施加压力

efforts in

努力在

the United States

美国

, but private investment is helping to fill the gap, with oncology ventures

，但私人投资正在帮助填补这一空白，其中肿瘤学领域的风险投资

securing hundreds of millions

获得数亿美元的担保

in funding so far in 2025. The Senate's recent

迄今为止，在2025年的资金。参议院最近的

restoration of

恢复

$15 million

1500万美元

for the

为了

Pancreatic Cancer Research Program (PCARP)

胰腺癌研究计划 (PCARP)

was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including

是一场胜利，但其早期的淘汰也突显了公众支持的脆弱性。在此背景下，投资者正重点关注那些拥有突出科学实力、坚实研发管道和清晰监管策略的公司，包括

Oncolytics Biotech Inc.

Oncolytics生物技术公司

(NASDAQ:

（纳斯达克：

ONCY

ONCY

) (TSX: ONC),

) (多伦多证券交易所：ONC)，

Iovance Biotherapeutics, Inc.

Iovance生物治疗公司

(NASDAQ:

（纳斯达克：

IOVA

IOVA

),

),

Fate Therapeutics, Inc.

命运治疗公司

(NASDAQ:

（纳斯达克：

FATE

命运

),

),

Inovio Pharmaceuticals, Inc.

Inovio制药公司

(NASDAQ:

（纳斯达克：

INO

INO

), and

），以及

Nektar Therapeutics

Nektar治疗公司

(NASDAQ:

（纳斯达克：

NKTR

NKTR

).

）。

Global Market Insights

全球市场洞察

estimates the

估计

global oncology market

全球肿瘤学市场

at

在

US$345.1 billion

3451亿美元

in 2025 and forecasts it will climb to

2025年，并预测它将攀升至

US$866.1 billion

8661亿美元

by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute

到2034年，以强劲的10.8%的复合年增长率增长。仅美国预计就将贡献

$377.1 billion

3771亿美元

to that total.

添加到那个总数。

Vision Research Reports

视觉研究报道

projects an

项目

even larger figure

更大的数字

for the global cancer drug sector, predicting it will surpass

对于全球抗癌药物领域，预计它将超越

US$900 billion

9000亿美元

in sales by 2034.

到2034年在销售方面。

Oncolytics Biotech Inc.

Oncolytics生物技术公司

(NASDAQ:

（纳斯达克：

ONCY

ONCY

) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset,

) (TSX: ONC) 已正式进入其发展历程中最关键的阶段——为其旗舰资产在一线转移性胰腺导管腺癌 (mPDAC) 中寻求可能支持注册的试验，

pelareorep

佩拉雷奥雷普

.

。

In its latest Q2 2025 report, the company

在公司最新的 2025 年第二季度报告中

confirmed

确认

it has begun formal discussions with the

它已开始正式讨论与

U.S. Food and Drug Administration (FDA)

美国食品药品监督管理局 (FDA)

aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025.

旨在最终确定一项关键的研究设计，预计试验启动活动最早将于2025年第四季度开始。

For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types.

对于投资者和潜在合作伙伴而言，这代表了从有希望的临床数据到在医学上最具挑战性的癌症类型之一中获得潜在监管批准的明确转变。

'We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year,' said

“我们已经完成了概念验证研究，将在今年剩余时间里全力冲刺以获得监管清晰度，”

Jared Kelly

杰瑞德·凯利

, CEO of

，首席执行官

Oncolytics

溶瘤病毒学

. 'As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors.'

“随着我们巩固知识产权，为pelareorep获得明确的注册路径，并让我们的GOBLET数据成熟，我们将确立自己作为胃肠道肿瘤唯一的平台免疫疗法的地位。”

The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically 'cold' tumors—those typically invisible to the immune system—into 'hot' tumors that can respond to immunotherapy.

对mPDAC的战略关注既反映了令人信服的临床结果，也反映了一个重要的市场机会。Pelareorep是一种系统递送的溶瘤病毒，旨在将免疫学上的“冷”肿瘤（通常对免疫系统不可见）转化为可以对免疫疗法产生反应的“热”肿瘤。

In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a .

在一线胰腺癌研究中，基于pelareorep的方案显示出了显著的21.9%的两年总生存率，相比之下。

9.2% historical benchmark

9.2% 历史基准

for standard chemotherapy alone.

仅用于标准化学疗法。

Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors..

更加引人注目的是，当 pelareorep 与化疗和检查点抑制剂联合使用时，研究人员记录到 62% 的客观缓解率——这一点尤为重要，因为检查点抑制剂目前尚未获批用于此适应症。这些结果源于 pelareorep 的双重机制：它既能在癌细胞内复制，又能激活身体对肿瘤的免疫反应。

'This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action,' said Dr.

“这一强大的数据集汇总了多项针对历史上对免疫治疗有抵抗力的癌症的研究，为pelareorep的免疫介导作用机制提供了确凿的验证，”博士说道。

Thomas Heineman

托马斯·海因曼

, Chief Medical Officer of

，首席医疗官

Oncolytics

溶瘤病毒

. 'We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.'

“我们观察到肿瘤活检证实的病毒复制、免疫细胞激活以及细胞毒性T细胞被招募到肿瘤微环境（TME）中——这些都与接受pelareorep治疗的转移性胰腺导管腺癌（PDAC）和HR+/HER2-乳腺癌患者中观察到的持久反应一致。”

Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from .

来自GOBLET和AWARE-1研究的转化数据展示了pelareorep如何改变肿瘤微环境，增加PD-L1表达、增强干扰素信号传导并动员血液中的肿瘤浸润淋巴细胞——这些变化与肿瘤缩小相关。这种机制验证结合生存数据。

over 1,100 patients

超过1100名患者

across multiple studies, has solidified the company's decision to prioritize this indication.

在多项研究中，已经巩固了公司优先考虑这一适应症的决定。

Oncolytics'

溶瘤病毒的

execution-focused strategy is being led by

以执行为重点的战略由以下人员领导

Jared Kelly

杰瑞德·凯利

and

和

Andrew Aromando

安德鲁·阿罗马多

, who both played key roles in

，这两位都在其中扮演了关键角色

Ambrx Biopharma's

安博生物制药公司的

US$2 billion

20亿美元

acquisition

收购

by

通过

Johnson & Johnson

强生公司

. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution..

凯利在今年早些时候被任命为首席执行官，而阿罗曼多最近以首席商务官的身份加入公司。为了与他们对资本效率的关注保持一致，该公司已经终止了其“市场内”和“信用额度”融资工具，称拥有足够的资源在没有近期股东稀释的情况下实现关键的里程碑。

Regulatory advantages are already in place to accelerate development. Pelareorep holds

监管优势已经到位，可以加快开发进程。Pelareorep持有

Fast Track

快速通道

and

和

Orphan Drug

孤儿药

designations for

指定用于

pancreatic cancer

胰腺癌

from the

来自

FDA

食品药品监督管理局

, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners.

，这意味着该机构已经认识到这种药物的潜力以及这一患者群体中严重的未满足需求。这些地位简化了审查过程，增强了该项目对潜在制药合作伙伴的吸引力。

The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a

背景突显了这一机会：胰腺癌仍然是最常见的致命癌症之一，而且

five-year survival rate of less than 14%

五年生存率不到14%

. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population.

与其他免疫疗法已经改变治疗的癌症不同，mPDAC在很大程度上对免疫治疗手段产生了抵抗——这使得pelareorep的免疫激活机制对该服务不足的患者群体尤其具有前景。

Back in July,

回到七月，

Oncolytics

溶瘤病毒

hosted a

举办了

key opinion leader event

关键意见领袖活动

featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment..

特邀胃肠道癌专家参与，评审了患者的生存结果和生物标志物验证。专家小组重申了 pelareorep 激活先天性和适应性免疫反应的机制在生物学上可靠，并且对于一线转移性胰腺癌治疗具有商业相关性。

With this latest milestone,

随着这一最新里程碑，

Oncolytics

溶瘤病毒

is entering a phase where

正在进入一个阶段，其中

FDA

食品药品监督管理局

feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC.

反馈意见将影响临床计划和潜在的商业合作。如果该机构接受公司提出的以总生存期终点为中心的试验框架，那么产生的研究可能会提供pelareorep在mPDAC市场潜力的决定性证据。

The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution,

公司预计将在2025年第三季度提供更新的临床时间表，试验启动活动可能最早在2025年第四季度开始。凭借引人注目的生存数据、到位的监管指定以及经验丰富的领导团队推动执行，

Oncolytics

溶瘤病毒

is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets.

正在为佩拉雷奥雷普在肿瘤学最具挑战性和服务不足的市场之一进行关键测试定位。

CONTINUED… Read this and more news for Oncolytics Biotech at:

持续更新... 阅读更多关于Oncolytics Biotech的新闻，请访问：

https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/

https://usanewsgroup.com/2023/10/02/纳斯达克上最被低估的溶瘤公司/

In other recent industry developments and happenings in the market include:

其他近期行业发展和市场动态包括：

Iovance Biotherapeutics, Inc.

Iovance生物治疗公司

(NASDAQ:

（纳斯达克：

IOVA

IOVA

)

)

reported

已报告

strong Q2 2025 results with

2025年第二季度强劲的结果

$60 million

6000万美元

in total product revenue, driven primarily by its breakthrough melanoma therapy Amtagvi, which treated over 100 patients in the second quarter.

总计产品收入，主要由其突破性的黑色素瘤疗法Amtagvi推动，该疗法在第二季度治疗了100多名患者。

'Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients,' said

“随着现有的ATC增长持续，以及大型社区实践开始治疗患者，Amtagvi和Proleukin在2025年下半年的增长将持续。”

Frederick Vogt

弗雷德里克·沃格特

, Ph.D., J.D., Interim President and CEO of

，哲学博士，法学博士，临时总裁兼首席执行官

Iovance

伊奥文斯

. 'We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs.'

“我们预计很快将获得首个美国以外的监管批准，并且仍按计划提供关于我们的临床项目的最新信息。”

The company's tumor-infiltrating lymphocyte (TIL) therapy—which uses a patient's own immune cells to fight cancer—generated

公司的肿瘤浸润淋巴细胞 (TIL) 疗法——利用患者自身的免疫细胞来对抗癌症——产生了

$54.1 million

5410万美元

in revenue and represents the first

收入，并代表了第一个

FDA

食品药品监督管理局

-approved T-cell therapy for solid tumors, offering new hope for advanced melanoma patients who have tried other treatments without success.

-获批的针对实体瘤的T细胞疗法，为那些尝试其他治疗无效的晚期黑色素瘤患者提供了新的希望。

With expanded clinical trials planned for lung cancer and endometrial cancer, plus international approvals expected in

随着针对肺癌和子宫内膜癌的扩展临床试验计划，以及国际批准预计将在

Canada

加拿大

and other markets,

和其他市场，

Iovance

伊欧兰斯

is positioned to bring its innovative cancer treatment to patients worldwide.

有望将其创新的癌症治疗方法带给全球患者。

Fate Therapeutics, Inc.

命运治疗公司

(NASDAQ:

（纳斯达克：

FATE

命运

) recently

）最近

announced

宣布

promising clinical progress for its off-the-shelf CAR T-cell therapy FT819, which showed lasting responses in lupus patients and received

其现成的CAR T细胞疗法FT819在狼疮患者中显示出持久的反应，并获得了令人鼓舞的临床进展，

FDA

食品药品监督管理局

clearance to begin trials for a solid tumor program targeting MICA/B proteins. While primarily focused on autoimmune diseases, the company's next-generation FT836 CAR T-cell therapy represents a significant advancement in cancer treatment as it's designed to target solid tumors without requiring harsh conditioning chemotherapy, potentially making the treatment safer and more accessible..

获得了针对MICA/B蛋白的实体瘤项目开始试验的许可。尽管主要专注于自身免疫疾病，该公司下一代FT836 CAR T细胞疗法代表了癌症治疗的重大进步，因为它旨在靶向实体瘤而无需进行强烈的预处理化疗，这可能使治疗更安全且更容易获取。

'Building on this momentum, we are also working closely with the

‘在此势头的基础上，我们还与

FDA

食品药品监督管理局

under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026,' said Bob Valamehr, Ph.D., MBA, President and CEO of

在我们的RMAT指定下，目标是于2026年启动FT819在系统性红斑狼疮（SLE）和狼疮性肾炎（LN）中的注册研究，”Bob Valamehr博士、工商管理硕士，总裁兼首席执行官表示。

Fate Therapeutics

命运治疗公司

.

。

'Additionally, we continue to strengthen our broader pipeline programs with an extended partnership with

“此外，我们通过与合作伙伴的深入合作，不断加强我们更广泛的渠道项目，

Ono Pharmaceuticals

小野药品工业公司

, and advancements in bringing our next-generation, off-the-shelf CAR T cells with Sword and Shield™ technology toward the clinic.'

`, 以及我们在将下一代、现成的带有 Sword and Shield™ 技术的 CAR T 细胞推向临床方面取得的进展。`

The company's stem cell-based platform continues to advance multiple programs, including partnerships for HER2-positive solid tumors, positioning

公司基于干细胞的平台继续推进多个项目，包括针对HER2阳性实体瘤的合作，定位

Fate

命运

as a leader in developing ready-made cancer cell therapies.

作为开发即用型癌症细胞疗法的领导者。

Inovio Pharmaceuticals, Inc.

Inovio制药公司

(NASDAQ:

（纳斯达克：

INO

INO

)

)

remains on track

保持正常

to submit its application for INO-3107 in the second half of 2025, targeting Recurrent Respiratory Papillomatosis (RRP), a rare cancer-related condition caused by HPV

计划在2025年下半年提交其针对由HPV引起的罕见癌症相关疾病——复发性呼吸道乳头状瘤病（RRP）的INO-3107申请。

that affects the airways

影响呼吸道的

. The company's DNA medicine platform represents a novel approach to treating HPV-related diseases and cancers, with INO-3107 showing significant clinical benefit by reducing the need for repeated surgeries in RRP patients from an average of 4.1 procedures annually to just 0.9 procedures.

公司的DNA药物平台代表了一种治疗HPV相关疾病和癌症的新方法，INO-3107通过将RRP患者每年平均需要进行的手术次数从4.1次减少到仅0.9次，展示了显著的临床益处。

'We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis (RRP) patients and their physicians—a treatment option with the potential to change the trajectory of this disease,' said Dr.

“我们相信，INO-3107可能成为复发性呼吸道乳头状瘤病（RRP）患者及其医生的首选治疗方案——这一治疗方案有潜力改变该疾病的进程，”博士表示。

Jacqueline Shea

杰奎琳·谢伊

, President and CEO of

，总裁兼首席执行官

INOVIO

艾诺维奥

. 'I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026.'

“我期待在上个季度取得的重大进展基础上继续努力，并在我们朝着2026年年中可能的批准日期努力的过程中提供更新。”

Beyond RRP,

超出建议零售价，

Inovio's

Inovio的

technology platform is designed to treat various HPV-related cancers and other tumors by teaching the body's immune system to recognize and fight cancer cells. With breakthrough therapy designation from the

技术平台旨在通过教导人体免疫系统识别和对抗癌细胞，来治疗各种与HPV相关的癌症和其他肿瘤。该平台已获得突破性疗法的认定。

FDA

食品药品监督管理局

and plans for a trial involving 100 patients, INO-3107 could become the first DNA-based therapy approved for treating this serious cancer-related condition.

针对涉及100名患者的试验计划，INO-3107可能成为首个获批用于治疗这种严重癌症相关疾病的DNA疗法。

Nektar Therapeutics

Nektar 治疗公司

(NASDAQ:

（纳斯达克：

NKTR

NKTR

)

)

reported

已报告

impressive Phase

令人印象深刻的阶段

2b

2b

data for rezpegaldesleukin in treating moderate to severe atopic dermatitis, with the company positioning this immune system regulator as a first-in-class treatment for autoimmune diseases. While primarily focused on autoimmune conditions,

治疗中重度特应性皮炎的rezpegaldesleukin数据，该公司将这种免疫系统调节剂定位为自身免疫性疾病的一线治疗方法。虽然主要关注自身免疫疾病，

Nektar's

Nektar的

pipeline

管道

includes NKTR-255, a treatment designed to boost the immune system's ability to fight cancer, which is being tested in multiple ongoing clinical trials with various partners.

包括旨在增强免疫系统抗癌能力的NKTR-255，该药物正与多个合作伙伴进行多项正在进行的临床试验。

'As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders,' said

“作为一流的T调节细胞生物制剂，rezpegaldesleukin有望成为治疗数百万自身免疫性疾病患者的重要新机制，”

Howard W. Robin

霍华德·W·罗宾

, President and CEO of

，总裁兼首席执行官

Nektar

花蜜

. 'Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target.'

“最后，我们正在通过一种新的双特异性抗体NKTR-0166取得显著进展，该抗体将TNFR2表位与经过验证的抗体靶点结合，推动临床前研究。”

The company's technology platform creates novel treatments that could potentially address both autoimmune diseases and cancer by enhancing the immune system's cancer-fighting abilities. With additional data expected from hair loss trials in

该公司的技术平台创造了可能通过增强免疫系统抗癌能力来应对自身免疫疾病和癌症的新疗法。随着预计从脱发试验中获得更多数据，

December 2025

2025年12月

and continued development of next-generation programs,

并继续开发下一代程序，

Nektar

花蜜

is advancing a unique approach to immune system therapy that could benefit millions of patients with serious diseases.

正在推进一种独特的免疫系统治疗方法，这种方法可能使数百万重症患者受益。

Source:

源代码：

https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/

https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/

CONTACT:

联系：

USA

美国

NEWS GROUP

新闻组

info@usanewsgroup.com

信息@美国新闻集团.com

(604) 265-2873

(604) 265-2873

DISCLAIMER:

免责声明：

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision.

本出版物中的任何内容均不应视为个性化的财务建议。我们并未根据证券法获得处理您特定财务状况的许可。我们员工对您的任何沟通均不应被视为个性化的财务建议。在做出任何投资决定之前，请咨询持有执照的财务顾问。

This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

这是一则付费广告，既不是购买或出售任何证券的要约，也不是推荐。我们未持有任何投资许可证，因此既未获许可也不具备提供投资建议的资格。本报告或电子邮件中的内容并非针对任何个人的具体情况提供。

.

。

USA

美国

News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock.

新闻集团是Market IQ Media Group, Inc.（“MIQ”）的全资子公司。MIQ已从Oncolytics Biotech Inc.直接获得广告和数字媒体费用。可能有第三方持有Oncolytics Biotech Inc.的股份，并可能抛售其股票，这可能会对股价产生负面影响。

This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc.

这种补偿构成了我们在关于这家重点公司的沟通中保持客观能力的利益冲突。由于这一冲突，强烈建议个人不要将本出版物作为任何投资决策的依据。MIQ的所有者/运营者持有Oncolytics Biotech Inc.的股份。

which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc.

这些股份是在公开市场上购买的，我们保留在任何时候买卖 Oncolytics Biotech Inc. 股票的权利，并将立即开始且持续进行买卖，不再另行通知。我们还预计会因持续的数字媒体推广活动以提高公司知名度而获得进一步报酬，虽然不会另行通知，但请以此免责声明作为通知：所有由 MIQ 发布的材料，包括本文，均已获得 Oncolytics Biotech Inc. 的批准；这是一则付费广告，我们目前持有 Oncolytics Biotech Inc. 的股份。

and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. .

并将在公开市场或通过私募方式和/或其他投资工具买卖公司股票。

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results.

虽然所有信息均被认为可靠，但我们不保证其准确性。个人应假定我们通讯中包含的所有信息均不可信，除非通过他们自己的独立研究进行核实。此外，由于事件和情况往往不会按预期发生，任何预测与实际结果之间可能存在差异。

Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment..

在做出任何投资决定之前，请务必咨询持有执照的投资专业人士。要格外小心，证券投资具有很高的风险，您可能会损失部分或全部投资。

Logo -

标志 -

https://mma.prnewswire.com/media/2603685/5460912/USA_News_Group_Logo.jpg

https://mma.prnewswire.com/media/2603685/5460912/USA_News_Group_Logo.jpg

SOURCE

源代码

USA

美国

News Group

新闻组

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用